ArticleEJHaem2026
Circulating CD117+/CD34+/CD45dim Myeloblasts as Biomarkers of Disease Activity in Primary Myelofibrosis-A Pilot Study.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Clinical benefit measures and surrogates for leukaemic transformation or overall survival are scarce in MF. Circulating myeloblast (CMB) counts have the biological plausibility to indicate disease evolution, but they are still determined by an outdated approach with microscopic examination and fixed cut-offs. Our aim was to evaluate the prognostic value of CD117+/CD34+/CD45dim CMBs (CMB-FC) as continuous variables in MF patients at diagnosis and during cytoreductive therapy. Methods: Absolute counts (CMB-FC#) and relative percentages (CMB-FC%) were determined using multiparameter flow cytometry (FC). Associations of CMB-FCs and well-established prognostic markers of MF were determined by linear regression and non-parametric tests. Longitudinal CMB-FC changes were analysed using linear mixed-effects models. Results: In the 29 analysed patients, meaningful correlations were observed between CMB-FCs and blood counts, Conclusion: This novel approach for quantifying CMBs has strong potential to reflect disease activity and prognosis in MF. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.